NCT05333549View on ClinicalTrials.gov

Istradefylline for Parkinson Disease With Cognitive Impairment

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

July 18, 2022

Primary Completion Date

June 9, 2025

Study Completion Date

June 9, 2025

Conditions
Parkinson DiseaseCognitive Impairment
Interventions
DRUG

Istradefylline medication

2 weeks on istradefylline 20mg daily, 2 weeks on istradefylline 40mg with the ability to adjust other antiparkinsonian medications, and 22 weeks on istradefylline 40mg and stable antiparkinsonian medications

Trial Locations (1)

23298

Virginia Commonwealth University, Richmond

Sponsors

Collaborators (1)

Kyowa Kirin, Inc.
All Listed Sponsors
collaborator

Kyowa Kirin, Inc.

INDUSTRY

lead

Virginia Commonwealth University

OTHER